福瑞股份(300049) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 80 million and 90 million yuan, representing a year-on-year growth of 83% to 105% compared to 43.82 million yuan in the same period of 2023[3] - The net profit after deducting non-recurring gains and losses is also expected to be between 80 million and 90 million yuan, reflecting a growth of 71% to 93% from 46.74 million yuan in the previous year[3] - The company has recognized share-based payment expenses of approximately 5.18 million yuan related to the 2024 restricted stock incentive plan, with the adjusted net profit attributable to shareholders estimated to be between 85 million and 95 million yuan after excluding this impact[4] - The impact of non-recurring gains and losses on net profit for the first half of 2024 is expected to be less than 1 million yuan[5] - The specific financial data for the first half of 2024 will be disclosed in the company's detailed semi-annual report[5] Business Development - The company is focusing on the development opportunities in the field of metabolic dysfunction-related fatty liver disease (MASH), enhancing the global demand for Fibroscan applications, which has led to sustained growth in equipment business revenue[4] - The liver disease pharmaceutical business has achieved both sales revenue and profit growth, aligning with the company's mission to keep families away from liver cancer[4]